If you’ve spent a year tracking a once-a-week shot, switching to a daily pill quietly changes the job. You go from one dosing event every seven days to seven a week, and for two of the three pills now on the US market, when and how you swallow it decides how much drug you actually get.
This article explains how oral GLP-1s work and how tracking them differs from injections. It is not medical advice and gives no dosing guidance. Your prescriber and pharmacist own the decisions specific to you.
Two oral options arrived fast. Novo Nordisk’s Wegovy pill (once-daily oral semaglutide, up to 25 mg) was the first oral GLP-1 cleared for weight loss, launching in the US in January 2026 on the OASIS 4 results. Eli Lilly’s Foundayo (orforglipron) followed in April, a different kind of molecule entirely. Rybelsus, the older oral semaglutide for type 2 diabetes, has been around longer. The three don’t behave the same way.
The fasting window is the new injection site
On a weekly shot, the fiddly part was rotating the site so you didn’t keep jabbing the same patch of skin. The pill drops that worry and adds a stricter one.
Oral semaglutide, both Rybelsus and the Wegovy pill, is barely absorbed. Roughly 1% of the dose makes it through the gut wall, ushered across by an absorption agent that only works on a genuinely empty stomach. So the label is exact: take it when you wake, with no more than 120 mL of plain water, then wait at least 30 minutes before any food, any other drink, or any other medication. Coffee in that window, a bigger glass of water, breakfast eight minutes early: each one drags absorption down. With a drug that starts at 1%, you don’t have much to give away.
That splits adherence into two questions. Did I take it, and did I take it right? A shot you either did or didn’t do. A semaglutide pill you can take every single morning and still under-dose yourself by getting the window wrong half the time. This is what Traqr is for. Log the dose, the time you took it, the water, and when you first ate. Then if a week stalls, your own log can show whether the mornings were mistimed or the dose just needs longer to work. A plain did-I-take-it tick can’t separate those two.
Orforglipron rewrites that rule. It’s a small molecule, not a peptide, and it doesn’t need the empty-stomach trick. You can take it any time of day, with or without food or water. Lilly leaned on that in its launch: the pill you can take without rearranging your morning. If you’re choosing between the two, the dosing discipline is worth weighing.
A missed dose doesn’t fade the same way
Your old injection instincts can mislead you here.
Injectable semaglutide hangs around for about a week, so the level still rises and falls across the dosing interval. It peaks a couple of days after the shot and drifts down to a trough by day seven. That’s the curve Traqr maps for you. The fluctuation is gentle compared to a daily drug, because the half-life is long enough that one missed day barely moves it. Oral semaglutide is the same molecule with that same long tail, so one skipped morning won’t crater you. But because daily absorption swings so much from one day to the next (within-person variability runs over 100%), the pill’s real blood level is a wobblier line than the injection’s ever was. The daily routine exists partly to average out that noise.
Orforglipron is the opposite shape. It clears in a few days, not a couple of weeks, so a missed dose drops off faster and a steady daily habit matters more for holding your level.
None of this is a reason to double up after a miss. That’s a prescriber question, and the answer differs by drug. The point for tracking is narrower: a calendar of daily ticks tells you less than it looks like it does, because the pills underneath aren’t interchangeable.
What carries over from your injection history, and what doesn’t
The instinct on switching is to map your old dose onto the new one. It doesn’t map. A 2.4 mg weekly Wegovy shot is not a 2.4 mg daily tablet. The route changes, and so do the numbers and the schedule. Oral Wegovy starts at 1.5 mg and steps up over months to 25 mg; orforglipron runs its own ladder from 0.8 mg. Most people restart titration on the pill rather than picking up where the injection left off, and the early weeks can bring back the nausea you thought you’d left behind at your old dose.
What does carry over is everything that was never about the needle: your weight trend, your side-effect patterns, what your appetite does at each step, which foods started making you queasy. That history is the useful part, and a switch shouldn’t wipe it.
This is the gap Traqr was built to close. The app already models all three oral GLP-1s (Rybelsus, oral Wegovy, and Foundayo) by their actual route, not as a generic pill. It knows oral semaglutide shares the injection’s long half-life but absorbs erratically, and that orforglipron clears faster, so the medication-level curve it draws reflects the pill you’re actually on. You log the daily dose and its timing, keep your weight and side-effect record running straight through the switch, and watch your level behave like a daily pill instead of guessing from a weekly mental model. Your weight is one line on the chart. On a daily pill, the timing around it is what fills in the rest.
Sources
- FDA / Novo Nordisk — Wegovy pill (once-daily oral semaglutide 25 mg) approval, first oral GLP-1 for weight loss; OASIS 4 results (~17% on-treatment, ~14% real-world). https://www.novonordisk.com/news-and-media/news-and-ir-materials.html
- FDA / Eli Lilly — Foundayo (orforglipron) approval, April 1 2026; the only oral GLP-1 for weight loss with no food or water restrictions. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
- Rybelsus / oral semaglutide administration (empty stomach, ≤120 mL water, 30-minute wait) — US prescribing information via the prescriber and pharmacist.